Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood

Volumn 116, Issue 22, 2010, Pages

  White, Helen E ^a   Matejtschuk, Paul ^b   Rigsby, Peter ^b   Gabert, Jean ^c,d   Lin, Feng ^a   Wang, Y Lynn ^e   Branford, Susan ^f   Müller, Martin C ^g   Beaufils, Nathalie ^c   Beillard, Emmanuel ^h,aa   Colomer, Dolors ⁱ   Dvorakova, Dana ^j   Ehrencrona, Hans ^k,ab   Goh, Hyun Gyung ^l   El Housni, Hakim ^m   Jones, Dan ⁿ   Kairisto, Veli ^o   Kamel Reid, Suzanne ^p   Kim, Dong Wook ^l   Langabeer, Stephen ^q   Ma, Edmond S K ^r   Press, Richard D ^s   Romeo, Giuliana ^t   Wang, Lihui ^u   Zoi, Katerina ^v   Hughes, Timothy ^f   Saglio, Giuseppe ^w   Hochhaus, Andreas ^x   Goldman, John M ^y   Metcalfe, Paul ^b   Cross, Nicholas C P ^a,z   more..

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d INSERM   (France)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h MolecularMD   (United States)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k UPPSALA UNIVERSITY   (Sweden)

^l The Catholic University of Korea   (South Korea)

^m ERASME HOSPITAL   (Belgium)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o TURKU UNIVERSITY HOSPITAL   (Finland)

^p UNIVERSITY HEALTH NETWORK   (Canada)

^q ST JAMES S HOSPITAL   (Ireland)

^r HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^s OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^t ROYAL PERTH HOSPITAL   (Australia)

^u ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^v Academy of Athens Biomedical Research Foundation   (Greece)

^w UNIVERSITY OF TURIN   (Italy)

^x JENA UNIVERSITY HOSPITAL   (Germany)

^y IMPERIAL COLLEGE LONDON   (United Kingdom)

^z UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^aa Singapore Graduate Medical School   (Singapore)

^ab LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; HUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WORLD HEALTH ORGANIZATION;

EID: 78649462136     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-291641     Document Type: Article

References (26)

1. O'Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009;7(9):984-1023.
2. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
3. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program. 2009;371-381.
4. Gabert J, Beillard E, van der Velden V, et al. Standardization and quality control studies of 'realtime' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
5. Cross NCP. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(3):355-365.
6. Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn. 2007;9(4):421-430.
7. Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica. 2007;92(7):970-973.
8. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
9. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-32.
10. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-1930.
11. Branford S, Fletcher L, Cross NCP, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
12. Hirsh J, Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med. 1994;154(3):282-288.
13. Müller MC, Cross NCP, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957-1963.
14. World Health Organization. WHO Expert Committee on Biological Standardization. World Health Organization Technical Report Series. 2006;932(v-vi):1-137.
15. Saldanha J, Silvy M, Beaufils N, et al. Characterization of a reference material for BCR-ABL (MBCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia. 2007;21(7):1481-1487.
16. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20(1):29-41.
17. White HE, Cross NCP. Freeze dried cell lines as reference materials for standardisation of BCRABL RQPCR methods: report of a field trial evaluation. 1-53. 2008. www.ngrl.org.uk/Wessex/downloads/pdf/NGRLW-NIBSC-BCR-ABL-1.0.pdf Accessed June 23, 2010.
18. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8(1):186-189.
19. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-599.
20. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13(11):1825-1832.
21. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol. 1995;91(1):126-131.
22. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99(4):945-950.
23. Malinge MC, Mahon FX, Delfau MH, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol. 1992;82(4):701-707.
24. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97(6):1560-1565.
25. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet. 1993;341(8840):275-276.
26. Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22(1):96-102.